Skip to main content
editorial
. 2023 Jun 27;13(4):269–273. doi: 10.34172/bi.2023.27494

Table 1. Some autoimmune-mediated diseases following COVID-19 vaccines .

Vaccine Type* Autoimmune disease Age Gender References
ChAdOx1 nCoV-19 Immune thrombocytopenia 50 Female 17
mRNA-BNT162B2 Arthritis flare 55 Male 20
mRNA-1273
mRNA-BNT162B2
ChAdOx1 nCov-19		 Autoimmune hepatitis 76
35
36		 Female
Female
Male		 21
22
23
mRNA-BNT162B2 Symmetric polyarthritis 49 Male 24
Exacerbation of Behçet’s disease 28 Male
Pericarditis 37 Male
Temporal arteritis-like disease 60 Male
Oligoarthritis 37 Female
Myocarditis 22 Male
mRNA-BNT162B2
ChAdOx1 nCov-19		 Guillain-Barre Syndrome 82
48		 Female
Male		 25
26
mRNA-BNT162B2 Graves' disease 34 Female 27
ChAdOx1 nCov-19 Granulomatous vasculitis 77 Male 28
mRNA-BNT162B2
ChAdOx1 nCov-19		 ANCA-associated vasculitis 78
63		 Female
Male		 29
30
ChAdOx1 nCov-19 Systemic lupus erythematosus 22 Female 31
mRNA-1273 Vasculitis 39
81		 Male
Male		 32
BBIBP-CorV Rheumatoid arthritis 85 Female 33
Palindromic rheumatism 39 Female
Adult-onset Still’s disease 39 Male
Systemic lupus erythematosus 71
46		 Female
Female
Peripheral seronegative spondyloarthritis 61 Female

* ChAdOx1 nCoV-19, AstraZeneca; mRNA-1273, Moderna; BNT162b2, BioNTech-Pfizer; BBIBP-CorV, Sinopharm.